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Introduction
Chronic migraine (CM) is a prevalent, disabling neurologi-
cal disorder. PREEMPT demonstrated efficacy & safety of
onabotulinumtoxinA (BOTOX®) for prophylaxis of head-
aches in adults with CM.
Objective
Assess patients who received all 5 treatment cycles and
completed PREEMPT clinical program.
Methods
PREEMPT (two phase 3 studies: 24-wk, double-blind,
placebo-controlled [DBPC], parallel-group phase, followed
by 32-wk, open-label phase) evaluated efficacy & safety of
onabotulinumtoxinA in CM (≥15 days/month with head-
ache lasting ≥4 hr/day). Patients were randomized (1:1) to
onabotulinumtoxinA (O) or placebo (P) every 12 wks for 2
cycles, followed by onabotulinumtoxinA for 3 cycles.
Multiple headache symptom measures were evaluated.
Results for the completer (5 cycles) subgroup of patients
are reported.
Results
Of 1384 total patients, 1005 received all 5 treatment cycles
[513 received O only (O/O); 492 received 2 cycles of P
then 3 cycles of O (P/O)]. Demographics were similar
between treatment groups. At Week 56, after all patients
were treated with onabotulinumtoxinA, there continued
to be significant between-group differences favoring O/O
vs P/O group for the following headache symptom
measures: mean change from baseline in frequencies of
headache days (-12.0 O/O, -11.1 P/O;p=0.035), migraine
days (-11.6 O/O, -10.7 P/O;p=0.038), moderate/severe
headache days (-11.0 O/O, -10.1 P/O;p=0.042). Treat-
ment-related adverse event rate was 28.5% for O vs 12.4%
for P in the DBPC phase and 34.8% for patients treated
with O for all 5 cycles throughout the 56-wk trials.
Conclusion/relevance
This subgroup analysis demonstrated statistically & clini-
cally meaningful improvements with onabotulinumtoxinA
treatment (5 cycles) vs placebo (2 cycles)/onabotulinumtox-
inA (3 cycles) for multiple headache symptom measures &
suggests that at Week 56, patients treated earlier with
onabotulinumtoxinA had better outcomes. Onabotulinum-
toxinA is an effective, safe, well-tolerated long-term
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